CytomX Q2 FY26 net loss widens to $20.67 million; revenue drops to $1.42 million
CTMX•Cash position and program updates
Cash, cash equivalents and investments fell to $330.3 million at June 30 from $346.7 million at March 31; runway is forecast into 2H 2028.
Varseta-M Phase 1 monotherapy update in advanced CRC is due by end-2026; the first registrational CRC study is targeted for 1H 2027.
Q2 revenue falls as collaboration activity eases
CytomX posted Q2 revenue of $1.42 million, down 92.4% year over year as collaboration activity eased.
Net loss attributable to common stockholders widened to $20.67 million; loss per share was $0.09.
Operating loss widened to $23.78 million as operating expenses rose to $25.2 million, led by R&D costs of $17.6 million.
Related News
AIG Q2 FY26 net income per share drops 10% to $1.78; General Insurance net premiums written rise 9% to $7.5 billion
AIG•
Main Street Capital Q2 FY26 net investment income rises 2% to $90.3 million
MAIN•
